Amitriptyline potently neutralizes distinct SARS-CoV-2 variants including D614G, Omicron BA.5, and Omicron XBB.1
Our findings demonstrate that amitriptyline neutralizes SARS-CoV-2 across multiple variants. These results support the potential of amitriptyline as a repurposed antiviral drug. Further clinical studies are warranted to evaluate its efficacy and safety in treating COVID-19 in humans.
Authors
- Ulf Dittmer (ORCID: https://orcid.org/0000-0001-9284-4849)
- Adalbert Krawczyk (ORCID: https://orcid.org/0000-0001-9502-9903)
- Katrin Anne Becker (ORCID: https://orcid.org/0000-0002-6317-7298)
- Carina Elsner
- Nadine Beckmann (ORCID: https://orcid.org/0000-0002-2747-0833)
- Carolin Sehl
- Erich Gulbins (ORCID: https://orcid.org/0000-0002-3117-1342)
- Markus Kamler (ORCID: https://orcid.org/0000-0001-6608-8496)
- Laura Thümmler (ORCID: https://orcid.org/0000-0003-2034-6255)
- Stephanie Kadow (ORCID: https://orcid.org/0000-0001-6430-1230)
- Matthias Soddemann
- Oliver Witzke (ORCID: https://orcid.org/0000-0002-1019-1301)
- Isabel Zydek
- R. N. Grüneberg
Institutions
- Essen University Hospital (DE)
- West German Heart and Vascular Center Essen (DE)
- Institute of Molecular Biology (DE)
- University of Duisburg-Essen (DE)
Publication Details
- Journal
- Frontiers in Microbiology
- Published
- 2025-08-04
- DOI
- https://doi.org/10.3389/fmicb.2025.1631947
- Citations
- 1
- Primary Topic
- Pharmacological Receptor Mechanisms and Effects
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- Deutsche Forschungsgemeinschaft
- Universität Duisburg-Essen
- Stiftung Universitätsmedizin Essen